Neurology Clinical Trials Market Report 2026

The neurology clinical trials market size has grown strongly in recent years. It will grow from $5.8 billion in 2025 to $6.21 billion in 2026 at a compound annual growth rate (CAGR) of 7%. The growth in the historic period can be attributed to growth in neurological disease prevalence, expansion of pharmaceutical research pipelines, increased investment in neurology drug development, availability of advanced imaging tools, rising participation in clinical research.

The neurology clinical trials market size is expected to see strong growth in the next few years. It will grow to $8.05 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to increasing use of AI-driven trial analytics, rising demand for faster trial execution, expansion of patient-centric trial models, growing integration of remote monitoring technologies, increasing focus on rare neurological conditions. Major trends in the forecast period include increasing adoption of adaptive clinical trial designs, rising use of digital patient monitoring tools, growing focus on biomarker-based neurology trials, expansion of decentralized clinical trial models, enhanced emphasis on real-world evidence generation.

The growing prevalence of neurological disorders is expected to drive the growth of the neurology clinical trials market in the coming years. Neurological disorders are conditions that affect the brain, spinal cord, or nerves, impairing the normal function of the nervous system. The rise in neurological disorders is primarily due to the aging population, as older adults are more vulnerable to age-related conditions such as Alzheimer’s and Parkinson’s disease. Neurology clinical trials play a key role in managing neurological disorders by evaluating new treatments, drugs, or interventions to improve diagnosis, manage symptoms, slow disease progression, and enhance patient outcomes. For example, in September 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, the number of Australians living with dementia is projected to more than double, increasing from 411,100 in 2023 to 849,300 by 2058. Of these, an estimated 315,500 will be men and 533,800 women. Therefore, the increasing prevalence of neurological disorders is fueling the growth of the neurology clinical trials market.

Key companies in the neurology clinical trials market are focusing on developing innovative solutions, such as monoclonal antibodies, to target specific neurological pathways, improve treatment efficacy, and accelerate the development of novel therapies. Monoclonal antibodies are laboratory-produced molecules engineered to recognize and bind to specific proteins or antigens, often used to precisely target disease mechanisms in treatments and diagnostics. For instance, in July 2024, Eli Lilly and Company, a US-based pharmaceutical company, launched Kisunla (donanemab-azbt) for the treatment of early symptomatic Alzheimer’s disease. The therapy slows cognitive and functional decline, allowing eligible patients more time to remain independent and engage in daily life. It works by targeting and reducing brain amyloid plaques, with clinical trials demonstrating up to a 35% slowing of disease progression compared to placebo in patients with less advanced disease.

In March 2025, CLARIO, a US-based healthcare company, acquired NeuroRx for an undisclosed amount. Through this acquisition, CLARIO aims to strengthen its leadership in imaging, expand its neuroscience capabilities, and better support the development of transformative drugs for neurological diseases. NeuroRx is a Canada-based clinical-stage pharmaceutical company engaged in neurology clinical trials.

Major companies operating in the neurology clinical trials market are AbbVie Inc., Sanofi S.A., Novartis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., IQVIA Holdings Inc., Biogen Inc., ICON plc., Syneos Health, Charles River Laboratories International Inc., Parexel International Corporation, CMIC Holdings Co. Ltd., Medpace Holdings Inc., PSI CRO AG., Supernus Pharmaceuticals Inc., Worldwide Clinical Trials LLC., Ergomed plc., Biotrial S.A.S., Clinilabs Drug Development Corporation, Lindus Health Ltd.

North America was the largest region in the neurology clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurology clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neurology clinical trials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the neurology clinical trials market by increasing costs of imported diagnostic imaging systems, clinical trial software platforms, medical devices, and specialized laboratory equipment. Research hospitals and contract research organizations in North America and Europe are most affected due to reliance on imported trial infrastructure, while Asia-Pacific faces higher costs for trial equipment sourcing. These tariffs are increasing study budgets and extending trial timelines. However, they are also promoting regional trial infrastructure development, local technology sourcing, and domestic innovation in clinical research tools.

The neurology clinical trials market research report is one of a series of new reports that provides neurology clinical trials market statistics, including neurology clinical trials industry global market size, regional shares, competitors with a neurology clinical trials market share, detailed neurology clinical trials market segments, market trends and opportunities, and any further data you may need to thrive in the neurology clinical trials industry. This neurology clinical trials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Neurology clinical trials refer to research studies conducted to evaluate the safety, efficacy, and outcomes of interventions such as drugs, therapies, or diagnostic tools for neurological disorders. These trials aim to advance treatment options for conditions affecting the brain, spinal cord, and nervous system.

The primary phases of neurology clinical trials are Phase I, Phase II, Phase III, and Phase IV. Phase I trials involve a small group of healthy volunteers or patients to assess a drug’s safety, dosage range, and side effects. In neurology, these trials are crucial for determining the tolerability of novel treatments targeting complex brain and nerve functions. Study designs include interventional, observational, and expanded access trials, focusing on indications such as epilepsy, Parkinson’s disease (PD), Huntington’s disease, stroke, traumatic brain injury (TBI), amyotrophic lateral sclerosis (ALS), muscle regeneration, and others. Key end users include hospitals, clinics, research institutes, and others.

The neurology clinical trials market consists of revenues earned by entities by providing services such as collecting and analyzing health data, monitoring patient safety, managing trial sites, regulatory consulting, and trial design and planning. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.